On November 16, 2022 GlycoNet, one of the world’s leaders in glycomics—the study of carbohydrates in living organisms—reported that one of its five start-up companies, GlyCa Biosciences Inc., has entered into a seed funding round with Huron Innovation Inc (Press release, GlycoNet, NOV 16, 2022, View Source;utm_medium=rss&utm_campaign=glyconet-start-up-glyca-biosciences-inc-and-huron-innovation-inc-partner-to-improve-prostate-cancer-detection [SID1234624159]). This collaboration will advance clinical research for a new blood test to improve early detection and diagnosis of clinically significant prostate cancer in patients, with the main goal of minimizing unnecessary invasive tissue biopsies. Considering that approximately one in eight Canadian men will develop prostate cancer during their lifetime1, this new blood test could significantly impact healthcare for Canadians.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Our vision is to see a blood test that will decide if a patient should undergo a prostate needle biopsy or spare them from further testing," says Dr. Hon S. Leong, Director of GlyCa Biosciences. "I am beyond ecstatic to see longstanding engagement from a federally funded organization such as GlycoNet combined with investment from Huron Innovation Inc. to make this dream of the perfect blood test come to clinical reality. Many resources went into developing these blood tests in order to make sure we have something worth trialing. The clinical trials funded by Huron Innovation and CIHR will hopefully transform the diagnostic pathway of prostate cancer and continue Canada’s reputation for strong and cutting-edge prostate cancer research."

"Huron Innovation is proud to partner with GlyCa Biosciences and be at the forefront of this groundbreaking technology to make a better method of prostate cancer detection," says Terence Wai, Director of Huron Innovation Inc. "The partnership will accelerate this promising research to make a difference and build a better future."

With support from GlycoNet, GlyCa Biosciences has been developing blood tests focused on prostate cancer detection since 2018. Huron Innovation has co-developed four pieces of technology with GlyCa Biosciences that form the foundation of the blood tests to be evaluated in the clinical trial. The technology involves contributions from four GlycoNet researchers across three provinces: Dr. John Klassen, University of Alberta; Dr. John Trant, University of Windsor; Dr. Karla Williams, University of British Columbia, and Dr. Hon S. Leong, Sunnybrook Health Sciences Centre / University of Toronto.

"This partnership is a shining example of how interdisciplinary collaboration across Canada, combined with investment in glycomics, can translate to tremendous impacts in health and the economy," says Dr. Elizabeth Nanak, CEO of GlycoNet. "I am pleased to see GlyCa Biosciences’ innovative blood tests come one step closer to being used in clinics to improve patient care."

On November 16, 2022 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported it will report its financial results for the third quarter of 2022 on November 23, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET (Press release, Nykode Therapeutics, NOV 16, 2022, View Source [SID1234624158]). A live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website: View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On November 16, 2022, Phio Pharmaceuticals Corp. (the "Company") reported that entered into a Subscription and Investment Representation Agreement (the "Subscription Agreement") with Robert J. Bitterman, its interim Executive Chairman, who is an accredited investor (the "Purchaser"), pursuant to which the Company agreed to issue and sell one (1) share of the Company’s Series D Preferred Stock, par value $0.0001 per share (the "Preferred Stock"), to the Purchaser for $1,750 in cash (Filing, 8-K, Phio Pharmaceuticals, NOV 16, 2022, View Source [SID1234624157]). The sale closed on November 16, 2022. Additional information regarding the rights, preferences, privileges and restrictions applicable to the Preferred Stock is set forth under Item 5.03 of this Current Report on Form 8-K and is incorporated herein by reference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Subscription Agreement contains customary representations and warranties and certain indemnification rights and obligations of the parties.

The foregoing summary of the Subscription Agreement does not purport to be complete and is subject to, and qualified in its entirety by, such document, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On November 16, 2022 NuCana plc (NASDAQ: NCNA) reported that financial results for the third quarter ended September 30, 2022 and provided an update on its broad clinical program with its transformative ProTide therapeutics (Press release, Nucana BioPharmaceuticals, NOV 16, 2022, View Source [SID1234624156]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As of September 30, 2022, NuCana had cash and cash equivalents of £50.8 million compared to £46.5 million as of June 30, 2022 and £60.3 million at December 31, 2021. NuCana continues to advance its various clinical programs and reported a net loss of £4.5 million for the quarter ended September 30, 2022, as compared to a net loss of £8.0 million for the quarter ended September 30, 2021. Basic and diluted loss per share was £0.09 for the quarter ended September 30, 2022, as compared to £0.15 per share for the quarter ended September 30, 2021.

"This year we have focused on advancing our transformative ProTides through the clinic and evaluating additional indications and combinations to expand our development program," said Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer. "Based on NUC-3373’s promising efficacy and favorable safety profile, we initiated two clinical studies: NuTide:323, a randomized Phase 2 trial of NUC-3373 in combination with irinotecan (NUFIRI) and bevacizumab for the second-line treatment of patients with colorectal cancer; and NuTide:303 a Phase 1b/2 study of NUC-3373 in combination with either pembrolizumab in patients with solid tumors or in combination with docetaxel in patients with non-small cell lung cancer (NSCLC). Furthermore, we entered the Phase 2 part of the NuTide:701 study which is investigating NUC-7738 as a monotherapy and in combination with pembrolizumab in patients with solid tumors."

Mr. Griffith continued: "We recently presented data at the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting that showed the promising anti-tumor activity and favorable safety profiles of both NUC-3373 and NUC-7738. We presented encouraging data for NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) from the NuTide:302 Phase 1b/2 study in patients with advanced colorectal cancer. We also presented positive data on NUC-7738 in patients with solid tumors, including melanoma, from the Phase 1 part of the Phase 1/2 NuTide:701 study. At the 34th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Annual Meeting in October, we presented data demonstrating that NUC-3373 is a more potent inhibitor of thymidylate synthase than pemetrexed in both adenocarcinoma and squamous subtypes of NSCLC. In addition, we presented data that demonstrate NUC-3373’s ability to increase the immunogenic cell death of lung cancer cells in combination with pembrolizumab."

Mr. Griffith concluded: "We are pleased with the progress we have made this year with NUC-3373 and NUC-7738. Based on these positive data updates, we have expanded our development programs and are rapidly advancing them as we progress towards our goal of providing more effective and safer treatment options for patients with cancer. With a cash runway that is expected to fund operations into 2025, we look forward to achieving numerous value-driving catalysts in the near future."

Anticipated Milestones: Q4 2022 and H1 2023

• NUC-3373 (a ProTide transformation of 5-FU)

In Q4 2022, NuCana expects to:

Commence enrollment in the randomized, controlled Phase 2 (NuTide:323) study of NUC-3373 in combination with other agents for the second-line treatment of patients with colorectal cancer;
Commence enrollment in the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with either pembrolizumab in patients with various solid tumors or in combination with docetaxel in patients with non-small cell lung cancer (NSCLC) to identify additional indications for development; and
Expand the Phase 1b/2 (NuTide:302) study of NUC-3373 in colorectal cancer patients, and evaluate NUC-3373-based regimens in combination with bevacizumab in second-line patients with colorectal cancer.
In the first half of 2023, NuCana expects to:

Announce data from the Phase 1b/2 (NuTide:302) study of NUC-3373 combined with leucovorin, bevacizumab and either irinotecan or oxaliplatin in second-line patients with colorectal cancer; and
Announce data from the Phase 1b/2 (NuTide:303) modular study of NUC-3373 in combination with either pembrolizumab in patients with various solid tumors or docetaxel in patients with non-small cell lung cancer (NSCLC) to identify additional indications for development.
• NUC-7738 (a ProTide transformation of 3’-deoxyadenosine)

In Q4 2022, NuCana expects to:

Commence enrollment in the Phase 2 part of the NuTide:701 study of NUC-7738 in combination with the PD-1 inhibitor pembrolizumab, in patients with solid tumors; and
Announce data from the Phase 2 part of the NuTide:701 study in patients with solid tumors treated with NUC-7738 monotherapy.
In the first half of 2023, NuCana expects to:

Announce data from the Phase 1 part of the NuTide:701 study of NUC-7738 in patients with solid tumors; and
Announce data from the Phase 2 part of the NuTide:701 study in patients with solid tumors treated with NUC-7738 monotherapy and NUC-7738 in combination with pembrolizumab.

On November 16, 2022 Eli Lilly and Company (NYSE: LLY) reported that it will attend the fifth annual Evercore ISI HealthCONx Conference on Wednesday, Nov. 30, 2022. Jacob Van Naarden, Lilly executive vice president and CEO of Loxo@Lilly, and David Hyman, M.D., chief medical officer, Loxo@Lilly, will participate in a fireside chat at 12:10 p.m., Eastern time (Press release, Eli Lilly, NOV 16, 2022, https://investor.lilly.com/news-releases/news-release-details/lilly-participate-evercore-isi-healthconx-conference [SID1234624154]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly’s Investor website at View Source A replay of the presentation will be available on this same website for approximately 90 days.